[What is certain in the topical eradication of MRSA from carriers?].
Dziekan
G
G
Institut für Umweltmedizin und Krankenhaushygiene, Universitätsklinikum Freiburg.
Mlangeni
D
D
Daschner
F D
FD
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002353:Carrier State / Q000188:drug therapy*; D003428:Cross Infection / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D017053:Infection Control; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D009666:Nose / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000517:prevention & control; D013207:Staphylococcal Skin Infections / Q000188:drug therapy / Q000517:prevention & control; D013211:Staphylococcus aureus / Q000187:drug effects*; D020713:Vancomycin Resistance; D014947:Wounds and Injuries / Q000382:microbiology
D000900:Anti-Bacterial Agents